Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jmii.2021.01.011 | DOI Listing |
Ther Adv Infect Dis
December 2024
Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
Background: Key populations (KP) are highly vulnerable to HIV acquisition and account for 70% of new infections worldwide. To optimize HIV prevention among KP, the World Health Organization recommends the combination of emtricitabine plus tenofovir disoproxil fumarate for pre-exposure prophylaxis (PrEP). However, PrEP failure could be attributed to drug resistance mutations (DRMs) but this is unexplored in sub-Saharan Africa (SSA).
View Article and Find Full Text PDFJ Infect Chemother
December 2024
Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, 113-8519, Tokyo, Japan. Electronic address:
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe illness and mortality in patients with immunodeficiency. Although vaccination has been recommended, the induction of protective antibodies by immunization, and thus the disease-preventive effect, has proven insufficient in immunodeficient patients, especially in those with predominantly antibody deficiency. A monoclonal antibody combination of tixagevimab and cilgavimab (TIX/CIL) was developed as a pre-exposure prophylaxis (PrEP).
View Article and Find Full Text PDFFront Reprod Health
November 2024
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Introduction: PrEP, a highly effective HIV prevention measure, provides autonomy to individuals in managing their HIV acquisition vulnerability. Despite its availability in tenofovir-based oral pills and injectable cabotegravir formulations, PrEP uptake among Black cisgender women in the U.S.
View Article and Find Full Text PDFExpert Rev Hematol
December 2024
Infectious Diseases, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.
Introduction: COVID-19 is a continuing challenge for immunocompromised patients with hematological malignancies. Such patients are at increased risk for complications, including hospitalization, respiratory failure, delayed anti-cancer therapies, and even death. In addition to non-pharmacologic interventions, the main strategies for prevention in such patients are vaccination and pre-exposure prophylaxis.
View Article and Find Full Text PDFCurr Biol
November 2024
Department of Life Science and Technology, School of Life Science and Technology, Institute of Science Tokyo, Yokohama 226-8501, Japan; Center for Integrative Biosciences, Institute of Science Tokyo, Yokohama 226-8501, Japan. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!